Cargando…
A high-affinity antibody against the CSP N-terminal domain lacks Plasmodium falciparum inhibitory activity
Malaria is a global health concern, and research efforts are ongoing to develop a superior vaccine to RTS,S/AS01. To guide immunogen design, we seek a comprehensive understanding of the protective humoral response against Plasmodium falciparum (Pf) circumsporozoite protein (PfCSP). In contrast to th...
Autores principales: | , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Rockefeller University Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7596816/ https://www.ncbi.nlm.nih.gov/pubmed/32790871 http://dx.doi.org/10.1084/jem.20200061 |
_version_ | 1783602192690708480 |
---|---|
author | Thai, Elaine Costa, Giulia Weyrich, Anna Murugan, Rajagopal Oyen, David Flores-Garcia, Yevel Prieto, Katherine Bosch, Alexandre Valleriani, Angelo Wu, Nicholas C. Pholcharee, Tossapol Scally, Stephen W. Wilson, Ian A. Wardemann, Hedda Julien, Jean-Philippe Levashina, Elena A. |
author_facet | Thai, Elaine Costa, Giulia Weyrich, Anna Murugan, Rajagopal Oyen, David Flores-Garcia, Yevel Prieto, Katherine Bosch, Alexandre Valleriani, Angelo Wu, Nicholas C. Pholcharee, Tossapol Scally, Stephen W. Wilson, Ian A. Wardemann, Hedda Julien, Jean-Philippe Levashina, Elena A. |
author_sort | Thai, Elaine |
collection | PubMed |
description | Malaria is a global health concern, and research efforts are ongoing to develop a superior vaccine to RTS,S/AS01. To guide immunogen design, we seek a comprehensive understanding of the protective humoral response against Plasmodium falciparum (Pf) circumsporozoite protein (PfCSP). In contrast to the well-studied responses to the repeat region and the C-terminus, the antibody response against the N-terminal domain of PfCSP (N-CSP) remains obscure. Here, we characterized the molecular recognition and functional efficacy of the N-CSP–specific monoclonal antibody 5D5. The crystal structure at 1.85-Å resolution revealed that 5D5 binds an α-helical epitope in N-CSP with high affinity through extensive shape and charge complementarity and the unusual utilization of an antibody N-linked glycan. Nevertheless, functional studies indicated low 5D5 binding to live Pf sporozoites and lack of sporozoite inhibition in vitro and in vivo. Overall, our data do not support the inclusion of the 5D5 N-CSP epitope into the next generation of CSP-based vaccines. |
format | Online Article Text |
id | pubmed-7596816 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Rockefeller University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-75968162020-11-10 A high-affinity antibody against the CSP N-terminal domain lacks Plasmodium falciparum inhibitory activity Thai, Elaine Costa, Giulia Weyrich, Anna Murugan, Rajagopal Oyen, David Flores-Garcia, Yevel Prieto, Katherine Bosch, Alexandre Valleriani, Angelo Wu, Nicholas C. Pholcharee, Tossapol Scally, Stephen W. Wilson, Ian A. Wardemann, Hedda Julien, Jean-Philippe Levashina, Elena A. J Exp Med Article Malaria is a global health concern, and research efforts are ongoing to develop a superior vaccine to RTS,S/AS01. To guide immunogen design, we seek a comprehensive understanding of the protective humoral response against Plasmodium falciparum (Pf) circumsporozoite protein (PfCSP). In contrast to the well-studied responses to the repeat region and the C-terminus, the antibody response against the N-terminal domain of PfCSP (N-CSP) remains obscure. Here, we characterized the molecular recognition and functional efficacy of the N-CSP–specific monoclonal antibody 5D5. The crystal structure at 1.85-Å resolution revealed that 5D5 binds an α-helical epitope in N-CSP with high affinity through extensive shape and charge complementarity and the unusual utilization of an antibody N-linked glycan. Nevertheless, functional studies indicated low 5D5 binding to live Pf sporozoites and lack of sporozoite inhibition in vitro and in vivo. Overall, our data do not support the inclusion of the 5D5 N-CSP epitope into the next generation of CSP-based vaccines. Rockefeller University Press 2020-08-13 /pmc/articles/PMC7596816/ /pubmed/32790871 http://dx.doi.org/10.1084/jem.20200061 Text en © 2020 Thai et al. https://creativecommons.org/licenses/by/4.0/This article is available under a Creative Commons License (Attribution 4.0 International, as described at https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Thai, Elaine Costa, Giulia Weyrich, Anna Murugan, Rajagopal Oyen, David Flores-Garcia, Yevel Prieto, Katherine Bosch, Alexandre Valleriani, Angelo Wu, Nicholas C. Pholcharee, Tossapol Scally, Stephen W. Wilson, Ian A. Wardemann, Hedda Julien, Jean-Philippe Levashina, Elena A. A high-affinity antibody against the CSP N-terminal domain lacks Plasmodium falciparum inhibitory activity |
title | A high-affinity antibody against the CSP N-terminal domain lacks Plasmodium falciparum inhibitory activity |
title_full | A high-affinity antibody against the CSP N-terminal domain lacks Plasmodium falciparum inhibitory activity |
title_fullStr | A high-affinity antibody against the CSP N-terminal domain lacks Plasmodium falciparum inhibitory activity |
title_full_unstemmed | A high-affinity antibody against the CSP N-terminal domain lacks Plasmodium falciparum inhibitory activity |
title_short | A high-affinity antibody against the CSP N-terminal domain lacks Plasmodium falciparum inhibitory activity |
title_sort | high-affinity antibody against the csp n-terminal domain lacks plasmodium falciparum inhibitory activity |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7596816/ https://www.ncbi.nlm.nih.gov/pubmed/32790871 http://dx.doi.org/10.1084/jem.20200061 |
work_keys_str_mv | AT thaielaine ahighaffinityantibodyagainstthecspnterminaldomainlacksplasmodiumfalciparuminhibitoryactivity AT costagiulia ahighaffinityantibodyagainstthecspnterminaldomainlacksplasmodiumfalciparuminhibitoryactivity AT weyrichanna ahighaffinityantibodyagainstthecspnterminaldomainlacksplasmodiumfalciparuminhibitoryactivity AT muruganrajagopal ahighaffinityantibodyagainstthecspnterminaldomainlacksplasmodiumfalciparuminhibitoryactivity AT oyendavid ahighaffinityantibodyagainstthecspnterminaldomainlacksplasmodiumfalciparuminhibitoryactivity AT floresgarciayevel ahighaffinityantibodyagainstthecspnterminaldomainlacksplasmodiumfalciparuminhibitoryactivity AT prietokatherine ahighaffinityantibodyagainstthecspnterminaldomainlacksplasmodiumfalciparuminhibitoryactivity AT boschalexandre ahighaffinityantibodyagainstthecspnterminaldomainlacksplasmodiumfalciparuminhibitoryactivity AT vallerianiangelo ahighaffinityantibodyagainstthecspnterminaldomainlacksplasmodiumfalciparuminhibitoryactivity AT wunicholasc ahighaffinityantibodyagainstthecspnterminaldomainlacksplasmodiumfalciparuminhibitoryactivity AT pholchareetossapol ahighaffinityantibodyagainstthecspnterminaldomainlacksplasmodiumfalciparuminhibitoryactivity AT scallystephenw ahighaffinityantibodyagainstthecspnterminaldomainlacksplasmodiumfalciparuminhibitoryactivity AT wilsoniana ahighaffinityantibodyagainstthecspnterminaldomainlacksplasmodiumfalciparuminhibitoryactivity AT wardemannhedda ahighaffinityantibodyagainstthecspnterminaldomainlacksplasmodiumfalciparuminhibitoryactivity AT julienjeanphilippe ahighaffinityantibodyagainstthecspnterminaldomainlacksplasmodiumfalciparuminhibitoryactivity AT levashinaelenaa ahighaffinityantibodyagainstthecspnterminaldomainlacksplasmodiumfalciparuminhibitoryactivity AT thaielaine highaffinityantibodyagainstthecspnterminaldomainlacksplasmodiumfalciparuminhibitoryactivity AT costagiulia highaffinityantibodyagainstthecspnterminaldomainlacksplasmodiumfalciparuminhibitoryactivity AT weyrichanna highaffinityantibodyagainstthecspnterminaldomainlacksplasmodiumfalciparuminhibitoryactivity AT muruganrajagopal highaffinityantibodyagainstthecspnterminaldomainlacksplasmodiumfalciparuminhibitoryactivity AT oyendavid highaffinityantibodyagainstthecspnterminaldomainlacksplasmodiumfalciparuminhibitoryactivity AT floresgarciayevel highaffinityantibodyagainstthecspnterminaldomainlacksplasmodiumfalciparuminhibitoryactivity AT prietokatherine highaffinityantibodyagainstthecspnterminaldomainlacksplasmodiumfalciparuminhibitoryactivity AT boschalexandre highaffinityantibodyagainstthecspnterminaldomainlacksplasmodiumfalciparuminhibitoryactivity AT vallerianiangelo highaffinityantibodyagainstthecspnterminaldomainlacksplasmodiumfalciparuminhibitoryactivity AT wunicholasc highaffinityantibodyagainstthecspnterminaldomainlacksplasmodiumfalciparuminhibitoryactivity AT pholchareetossapol highaffinityantibodyagainstthecspnterminaldomainlacksplasmodiumfalciparuminhibitoryactivity AT scallystephenw highaffinityantibodyagainstthecspnterminaldomainlacksplasmodiumfalciparuminhibitoryactivity AT wilsoniana highaffinityantibodyagainstthecspnterminaldomainlacksplasmodiumfalciparuminhibitoryactivity AT wardemannhedda highaffinityantibodyagainstthecspnterminaldomainlacksplasmodiumfalciparuminhibitoryactivity AT julienjeanphilippe highaffinityantibodyagainstthecspnterminaldomainlacksplasmodiumfalciparuminhibitoryactivity AT levashinaelenaa highaffinityantibodyagainstthecspnterminaldomainlacksplasmodiumfalciparuminhibitoryactivity |